The present invention relates to pharmaceutical compounds, compositions, combinations, and methods, especially as they are related to compositions and methods for the treatment and/or prevention of conditions such as gout that are associated with excessive levels of uric acid. The invention provides compounds of Formula (I) as further described herein, which inhibit activity of urate reabsorption transporter 1 (URAT1, also known as SLC22A12). The compounds are useful to treat conditions associated with excessive levels of uric acid, such as gout.
本发明涉及制药化合物、组合物、组合以及方法,特别是涉及与含有过多
尿酸相关的痛风等疾病的治疗和/或预防的组合物和方法。本发明提供了式(I)的化合物,如下文所述,该化合物抑制
尿酸重吸收转运蛋白1 (URAT1,也称为SLC22
A12)的活性。这些化合物可用于治疗与
尿酸含量过高相关的疾病,如痛风。